Using Lumbrokinase to treat Long Covid, Lyme Disease, and Chronic Fatigue Syndrome
Official title: Investigating the Effects of Lumbrokinase in Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Run by Icahn School of Medicine at Mount Sinai · NCT06511050 · Data updated 2026-11-12
This study is testing if a treatment called Lumbrokinase can help adults with Long Covid, Lyme Disease, and Chronic Fatigue Syndrome feel better and improve their quality of life.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | October 9, 2024 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | March 13, 2026 |
| Trial ID | NCT06511050 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with Long Covid, Post-treatment Lyme Disease Syndrome, or Chronic Fatigue Syndrome.
✕Probably not a fit
Patients who do not meet the diagnostic criteria for the specified conditions or have a baseline EQ-VAS score above 70 may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot multi-arm clinical trial investigates the feasibility of Lumbrokinase (LK) as a treatment for three specific conditions: Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Participants aged 18 and older, who meet specific diagnostic criteria for these conditions, will receive Lumbrokinase to assess its effectiveness. The study aims to evaluate the potential benefits of LK in improving symptoms and quality of life for affected individuals.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from Long Covid, Lyme Disease, and Chronic Fatigue Syndrome.
How similar studies have gone: While this approach is novel, there is limited existing research on Lumbrokinase for these specific conditions, making this trial an important exploratory effort.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Any gender
* Aged 18+
* Baseline EQ-VAS ≤70; EQ-VAS before the index infection ≥80 (this information is collected as part of the baseline survey).
* Diagnosed with only one of the following conditions:
* Long Covid
* Documented clinical history of confirmed or suspected acute COVID-19 infection a minimum of 3 months prior to contact with the study team
* Formal diagnosis of Long Covid from a physician
* Post-treatment Lyme disease syndrome
* Diagnosis will be based on participants meeting either Group 1 or Group 2 criteria of the Columbia Clinical Trial Network PTLDS diagnostic criteria:
* Group 1. Well-defined Lyme disease meeting CDC Surveillance Definition Erythema Migrans History of possible exposure to a high incidence county or state (or an adjacent area) Erythema migrans rash
* EM 1: EM rash diagnosed by HCP previously (either in person or telemedicine)
* EM 1A: MOA self-report \& medical record documentation of rash \> 5 cm
* EM 1B: MOA: self-report and medical record documentation of EM rash but not size
* EM 1C: MOA: self-report \& rash misdiagnosed in medical record as cellulitis/spider bite
* EM 1D: MOA: self-report and either: photo of EM or Class 1 lab test confirmation within 4 weeks of illness onset OR
* Disseminated "objective" manifestation with lab test confirmation of Bb infection
* Clinical history includes at least one of the following symptoms/signs, which are not better accounted for by another cause (MOA: medical records and/or self-report).
* Neurologic: Lymphocytic Meningitis ; Encephalitis; Encephalomyelitis Cranial Neuritis (especially facial palsy); Radiculoneuropathy; Other Neurologic Signs (with objective measures) : Encephalopathy, Polyneuropathy
* Carditis: 2nd or 3rd degree AV block; Myocarditis; Pericarditis
* Lyme arthritis: Recurrent joint swelling in one or more joints
* Dermatologic: Disseminated EM ("satellite") or Acrodermatitis atrophicans AND
* Lab test Confirmation (requires at least one of the Class 1 lab tests) (MOA: self-report \& documentation)
* Group 2. Probable
* 2A. Chronic Multisystem Symptoms attributed to Lyme disease (insufficient to meet Group 1) and not better explained by another diagnosis and patient has evidence of positive lab results on a Class 1 lab test (or 4 of 10 bands for IgG Western blot (WB)) (MOA: self-report with lab documentation Class 1 lab test confirmation (excluding IgM WB) Highly suggestive IgG WB (4 of 10 bands) OR
* 2B. EM rash by history after exposure to a Lyme-endemic area but not previously diagnosed by a HCP and no photo or Class 1 lab test confirmation is available (MOA: self-report) OR
* 2C. Viral like illness (not better explained by other cause) with indeterminate or + enzyme immunoassay (EIA) with positive IgM WB or positive Class 1 lab test (within 4 weeks of illness onset after known exposure to a Lyme high-incidence area for standard two-tiered (STT) IgM) (MOA: medical records, lab test and self-report) (MOA: lab test and self-report) OR
* 2D. Viral like illness (not better explained by other cause) with indeterminate or positive EIA with positive IgM WB or positive Class 1 lab test (within 6 months of illness onset after known exposure to a Lyme high-incidence area for standard two-tiered (STT) IgM)
* (MOA: medical records, lab test and self-report)
* (MOA: lab test and self-report)
* ME/CFS
* Formal diagnosis of ME/CFS prior to 2020 from a physician
* Actively symptomatic such that the 2011 International Criteria for ME/CFS is met at time of screening
Exclusion Criteria:
* Current use of antiplatelet or anticoagulation regimen
* Diagnosis of an autoimmune condition such as Chronic EBV, Multiple Sclerosis, Hashimoto's Disease, etc. which would impact the immunological profiling analysis.
* Pregnancy or lactation
* Known allergy to earthworms (Lumbrokinase is a supplement that is derived from earthworms)
* Past medical history of a bleeding or clotting disorder
* Has a scheduled surgery during, or immediately after, the study period
Where it's running
-
The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)
New York, New York, United States Recruiting
Study contacts
- Principal investigator: David Putrino, PhD, PT — Icahn School of Medicine at Mount Sinai
- Study coordinator: David Putrino, PhD, PT
- Email: CoreResearch@mountsinai.org
- Phone: 212-241-8454
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
A study using wearable devices to manage Long COVID symptoms
This study is testing if using wearable devices can help people with Long COVID manage their symptoms and improve their quality of life.
-
A 3-day course for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
This study is testing if a 3-day program called the Lightning Process can help adults with Chronic Fatigue Syndrome feel better and improve their daily lives.
-
A platform for collecting health data on ME/CFS and Long Covid
This study is trying to collect health information from adults with ME/CFS and Long Covid to help researchers better understand these conditions and improve future treatments.
-
Whole-body Cryotherapy for Fatigue in ME/CFS, Fibromyalgia, Long COVID
This study tests whether brief, repeated exposure to extreme cold can help reduce fatigue and related symptoms in adults with ME/CFS, fibromyalgia, or Long COVID compared to healthy controls.
-
Fatigue Investigation Using Digital Outcomes
This study tests whether digital monitoring with a smartphone app and wearables can track fatigue in people with MS or long COVID, compared with healthy volunteers.
-
Biomarker study to understand Long COVID using VIPER
This study tests biomarkers in people with Long COVID and those who recovered from COVID-19 to see how they can diagnose and track the condition over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.